Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast CancerOlivia Pagani, Prudence A. Francis, Eva Ciruelos et al.|New England Journal of Medicine|2014Cited by 751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast CancerPrudence A. Francis, Meredith M. Regan, Olivia Pagani et al.|New England Journal of Medicine|2018Cited by 684
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Rolf A. Stahel, Urania Dafni et al.|The Lancet Respiratory Medicine|2017Cited by 184
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT TrialsOlivia Pagani, Prudence A. Francis, Barbara Walley et al.|Journal of Clinical Oncology|2022Cited by 159
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, <i>ERBB2</i>-Negative Metastatic Breast CancerElisabetta Munzone, L. J. Blacher, Meredith M. Regan et al.|JAMA Oncology|2023Cited by 37